title: A combination of intravitreal bevacizumab injection with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
abstract: OBJECTIVE
  The purpose of this study was to investigate the effectiveness of intravitreal bevacizumab injections combined with tunable argon yellow laser photocoagulation as a treatment for adult-onset Coats' disease.
  
  
  METHODS
  We consecutively treated 3 patients suffering from Coats' disease diagnosed in adulthood with a combination of intravitreal bevacizumab injection and tunable argon yellow laser photocoagulation. All patients received an intravitreal injection of 2.5 mg bevacizumab together with various sessions of laser photocoagulation targeting the area of telangiectasia. The patients' best-corrected visual acuities were recorded. Fundus photography, fluorescein angiography (FA), and optical coherence tomography were used to monitor vascular and retinal exudate changes.
  
  
  RESULTS
  Fundus photography and FA of all 3 patients revealed significant regression of the vascular dilatation and the aneurysmal appearance of the telangiectasia areas. Optical coherence tomography also showed a significant subsidence of the macular edema and submacular fluid in all patients. A concomitant improvement in visual acuity was also noted. No treatment-related complications were identified.
  
  
  CONCLUSIONS
  Combining intravitreal bevacizumab and tunable argon yellow laser photocoagulation is an efficient treatment of choice for Coats' disease that has been diagnosed in adulthood.
authors.affiliation: Department of Ophthalmology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
authors.forename: Kai-Yun
authors.initials: KY
authors.lastname: Wang
authors.forename: Cheng-Kuo
authors.initials: CK
authors.lastname: Cheng
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D054025:Lasers, Dye / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010781:Photography; D058456:Retinal Telangiectasis / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014792:Visual Acuity; D055815:Young Adult
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab